Form 4: Glaukos Corp Executive Alex R. Thurman Reports Stock Option Grants and RSU Vesting
SEC Form 4 Filing
Alex R. Thurman, SVP & CFO of Glaukos Corporation, reports the acquisition of stock options and vesting of restricted stock units.
Summary
- On March 14, 2024, Alex R. Thurman, SVP & CFO of Glaukos Corporation, reported transactions involving Glaukos Corp [GKOS] securities.
- Thurman acquired 4,955 shares of Common Stock through the vesting of restricted stock units (RSUs).
- He was also granted stock options to purchase 1,830 shares at $55.18, 8,906 shares at $49.51, and 8,591 shares at $85.78.
- Following these transactions, Thurman beneficially owns 58,990 shares of Common Stock and various stock options.
- The stock options have different vesting schedules and expiration dates, extending to April 2033 and March 2034.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices. The vesting of RSUs and granting of stock options are generally positive as they align executive interests with shareholder value. No immediate concerns are raised.
Positives
- The vesting of RSUs and granting of stock options to a key executive could be seen as a positive sign, aligning the executive's interests with those of the shareholders.
- The vesting of options tied to performance targets suggests the company is achieving its operational goals.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of the stock options and RSUs suggest continued employment and alignment with company performance over the coming years.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the corporate world, particularly in publicly traded companies like Glaukos. These instruments are used to incentivize executives to improve company performance and align their interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are common in the medical device industry to attract and retain talent.
- Companies like Alcon, Johnson & Johnson (medical device segment), and Medtronic also utilize similar compensation strategies.
- The vesting schedules and exercise prices of the options are generally in line with industry standards for companies of Glaukos' size and stage of development.
Stakeholder Impact
- Shareholders: The transactions could have a minor dilutive effect if the options are exercised, but also incentivize the executive to improve company performance.
- Employees: The granting of stock options to executives can boost morale and align interests across the company.
- Executive: The executive benefits from the potential upside of the stock options and the value of the vested RSUs.
Key Dates
| Date | Description |
|---|---|
| 03/24/2022 | Date of previous grant of stock options, a portion of which vested on 03/14/2024. |
| 04/03/2023 | Date of previous grant of stock options as part of the Reporting Person's election to receive a portion of his annual bonus for 2023 in the form of stock options rather than cash. |
| 03/14/2024 | Date of the reported transactions, including RSU vesting and stock option grants. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
| 03/24/2032 | Expiration date for a portion of the stock options granted on March 24, 2022. |
| 04/03/2033 | Expiration date for the stock options granted on April 3, 2023. |
| 03/14/2034 | Expiration date for the stock options granted on March 14, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.